Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [5]. Core Insights - The PD-1 (PD-L1)/VEGF dual antibody concept is gaining significant attention, with Chinese innovative pharmaceutical companies leading the research and development efforts [2][20]. - The global market for dual antibodies is projected to exceed $80 billion by 2030, with PD-1 (PD-L1)/VEGF drugs expected to challenge traditional PD-1/PD-L1 therapies in cancer treatment [20][21]. - The report highlights the importance of clinical data barriers and international expansion for companies in this sector, suggesting that these factors will create differentiated investment opportunities [3][26]. Summary by Sections Market Review - The pharmaceutical and biotechnology index rose by 2.21%, outperforming the CSI 300 index by 3.30 percentage points [11][12]. - Among sub-industries, other biological products led with a 4.65% increase, while offline pharmacies saw a decline of 2.69% [12][19]. Clinical Progress - Notable advancements include the IND applications for BG-60366 by BeiGene and RFUS-949 by Renfu Pharmaceutical, as well as ongoing clinical trials for several drugs [29][30]. - Companies like Hengrui Medicine and Shijiazhuang Yiling Pharmaceutical are in Phase III trials, while others are in earlier stages [29][31]. Investment Strategy - The report emphasizes a structural selection of investment opportunities based on payment willingness and ability, focusing on three payment channels: hospital payments, out-of-pocket payments, and overseas payments [4][26]. - Key recommendations include Hengrui Medicine, Mindray Medical, United Imaging Healthcare, and Yuyue Medical [4]. Company Updates - Recent announcements include significant collaborations and product approvals, such as the $60.5 billion global licensing deal between 3SBio and Pfizer [2][28]. - The report notes that as of June 1, 2025, there are 14 PD-1 (PD-L1)/VEGF products in clinical stages, all associated with Chinese companies [21][24].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [5]. Core Insights - The PD-1 (PD-L1)/VEGF dual antibody concept is gaining significant attention, with Chinese innovative pharmaceutical companies leading the research and development efforts [2][20]. - The global market for dual antibodies is projected to exceed $80 billion by 2030, with PD-1 (PD-L1)/VEGF drugs expected to challenge the traditional PD-1/PD-L1 drugs in cancer treatment [20][21]. - The report highlights the importance of clinical data barriers and international expansion for companies in this sector, suggesting that these factors will create differentiated investment opportunities [3][26]. Summary by Sections Market Review - The pharmaceutical and biotechnology index rose by 2.21%, outperforming the CSI 300 index by 3.30 percentage points and the ChiNext index by 2.00 percentage points, ranking second among 31 sub-industries [11][12]. Clinical Progress - Notable advancements include the IND applications for BG-60366 by BeiGene and RFUS-949 by Renfu Pharmaceutical, as well as ongoing clinical trials for various drugs by companies like Hengrui Medicine and Stone Pharmaceutical [29][30]. Key Developments - The report notes that 14 PD-1 (PD-L1)/VEGF products are currently in clinical stages, all associated with Chinese companies, with the fastest progress seen in Ivonescimab by Kangfang Biotech, which has been approved in China [21][22]. Investment Strategy - The report emphasizes a structural selection of investment opportunities based on payment willingness and ability, focusing on three payment channels: hospital payments, out-of-pocket payments, and overseas payments [4][26]. - Recommended companies include Hengrui Medicine, Mindray Medical, United Imaging Healthcare, and Yuyue Medical [4]. Company Announcements - Recent announcements include various companies receiving approvals for new drugs and medical devices, indicating ongoing innovation and regulatory progress within the sector [28][29].

Market Overview - On June 3, A-shares saw a collective rebound with the Shanghai Composite Index rising by 0.43% to 3361.98 points, the Shenzhen Component Index increasing by 0.16% to 10057.17 points, and the ChiNext Index gaining 0.48% to 2002.7 points [2][3] - The total market turnover reached 116.38 billion yuan, an increase of 4 billion yuan compared to the previous day, with nearly 3400 stocks rising [2] Sector Performance - The leading sectors included precious metals, football concepts, gaming, banking, and innovative pharmaceuticals, while steel and automotive sectors experienced declines [2] - The gold concept led the gains, and the innovative pharmaceutical sector remained active, with new consumption concepts also reaching historical highs [2] International Market - The U.S. stock market indices closed higher on June 3, with the Dow Jones Industrial Average up by 0.51%, the S&P 500 up by 0.58%, and the Nasdaq Composite up by 0.81% [2] - European markets also saw gains, with the UK FTSE 100 rising by 0.15%, the French CAC 40 up by 0.34%, and the German DAX up by 0.67% [2] Commodity Prices - As of June 3, the price of light crude oil for July delivery on the New York Mercantile Exchange closed at $63.41 per barrel, an increase of 1.42%, while the August delivery of Brent crude oil closed at $65.63 per barrel, up by 1.55% [2] Regulatory Developments - The U.S. announced an increase in import tariffs on steel and aluminum from 25% to 50%, effective June 4, 2025, while maintaining the 25% tariff on imports from the UK [4][5] - China's Ministry of Foreign Affairs responded to concerns about rare earth export restrictions, indicating that inquiries should be directed to relevant authorities [5] Policy Initiatives - A joint initiative by five Chinese ministries aims to promote the use of new energy vehicles in rural areas, focusing on building a green, low-carbon, and intelligent transportation system [6] - The National Development and Reform Commission and the National Energy Administration issued opinions to support the application of green electricity and encourage key energy-consuming units to utilize green power [9][10] Investment Insights - Citic Securities highlighted a focus on low-valuation intelligent application targets in the robotics sector, while also noting the appeal of high-dividend assets in a declining interest rate environment [11] - CICC suggested that the market may maintain a volatile pattern, with a focus on sectors less affected by tariffs, such as AI infrastructure and certain export chains [11]

Group 1 - In May, 696 out of 1025 comparable ordinary equity funds achieved positive performance, representing 68% of the total [1] - The pharmaceutical-themed funds led the performance, with 15 funds showing monthly gains exceeding 10%, including Anxin Pharmaceutical Health Stock A and C, and Hongtu Innovation Medical Care Stock [1] - Anxin Pharmaceutical Health Stock A and C had gains of 15.35% and 15.31% respectively, while Hongtu Innovation Medical Care Stock gained 15.01% [1] Group 2 - Penghua Pharmaceutical Technology Stock A and C increased by 12.44% and 12.40% respectively, managed by veteran fund manager Jin Xiaofei [2] - Other notable pharmaceutical-themed funds with significant gains include Jianxin Medical Health Industry Stock and Invesco Great Wall Medical Industry Stock [2] - Funds heavily invested in technology stocks, such as Huian Trend Power Stock A and C, underperformed with declines of 9.74% and 9.69% respectively [2] Group 3 - Funds focused on advanced manufacturing and semiconductor industries, such as GF Advanced Manufacturing Stock and Chuangjin Hexin Chip Industry Stock, experienced declines ranging from 8.56% to 7.09% [3] - The top holdings of GF Advanced Manufacturing Stock include leading companies in manufacturing and technology sectors [3] - Financial performance of the funds in the semiconductor sector showed significant changes, with some funds experiencing a net value drop of 13.98% in the first quarter [3] Group 4 - The performance rankings of ordinary equity funds in May highlighted the top gainers and losers, with Anxin Pharmaceutical Health Stock A leading the gains [4] - The data indicates a clear trend where pharmaceutical funds outperformed technology-focused funds during this period [4] - The overall market sentiment reflected a preference for healthcare-related investments amid broader market fluctuations [4]

Core Insights - The Shanghai Composite Index rose by 0.43% on June 3, with 20 out of 28 sectors experiencing gains, particularly in the beauty care and textile sectors, which increased by 3.86% and 2.53% respectively [1] - The pharmaceutical and biotechnology sector saw a rise of 1.78%, with a net inflow of 9.17 billion yuan in capital [1] - Among the 475 stocks in the pharmaceutical sector, 416 stocks increased, with 14 hitting the daily limit up, while 54 stocks declined [1] Capital Flow Analysis - The pharmaceutical sector had 221 stocks with net capital inflows, with 6 stocks receiving over 100 million yuan in net inflows. Leading the inflow was Huahai Pharmaceutical with 266.1 million yuan, followed by Qianhong Pharmaceutical and Hehua Co., which received 201.5 million yuan and 168 million yuan respectively [1] - The outflow list included 6 stocks with net outflows exceeding 50 million yuan, with the highest outflows from Ruizhi Pharmaceutical, Hengrui Medicine, and Mindray Medical, which saw outflows of 237 million yuan, 110 million yuan, and 109 million yuan respectively [2] Pharmaceutical Sector Performance - The top gainers in the pharmaceutical sector included: - Huahai Pharmaceutical: +7.63%, turnover rate 7.71%, capital flow 266.1 million yuan - Qianhong Pharmaceutical: +10.05%, turnover rate 17.02%, capital flow 201.5 million yuan - Hehua Co.: +9.95%, turnover rate 18.47%, capital flow 167.7 million yuan [1] - The top decliners included: - Ruizhi Pharmaceutical: -13.15%, turnover rate 34.15%, capital flow -236.7 million yuan - Hengrui Medicine: -0.26%, turnover rate 0.68%, capital flow -109.7 million yuan - Mindray Medical: -3.02%, turnover rate 0.58%, capital flow -108.9 million yuan [2] ETF Insights - The Hang Seng Medical ETF, which tracks the Hang Seng Hong Kong-listed biotechnology index, experienced a 5-day increase of 3.59% with a net inflow of 9.86 million yuan [5]

Core Viewpoint - The cell immunotherapy sector has shown significant growth, with a 3.87% increase, ranking second among concept sectors, driven by strong performances from several stocks [1][2]. Group 1: Sector Performance - As of June 3, the cell immunotherapy concept saw 51 stocks rise, with notable gainers including Shutaishen and Guanhao Biological, both reaching a 20% limit up [1]. - Other top performers in the sector included Hainan Haiyao, Rui Zhi Pharmaceutical, and Zuo Li Pharmaceutical, with increases of 9.97%, 13.15%, and 10.66% respectively [1][2]. - Conversely, stocks like Xue Rong Biological, *ST Biological, and Fosun Pharmaceutical experienced declines of 1.76%, 1.14%, and 0.39% respectively [1]. Group 2: Capital Flow - The cell immunotherapy sector attracted a net inflow of 269 million yuan, with 34 stocks receiving significant capital inflows [2]. - Leading the net inflow was Huahai Pharmaceutical, which saw 266 million yuan enter, followed by Guanhao Biological and Hainan Haiyao with inflows of 159 million yuan and 64.85 million yuan respectively [2][3]. - The highest net inflow ratios were recorded for ST Zhongzhu, Hainan Haiyao, and Huahai Pharmaceutical, at 15.16%, 13.79%, and 12.53% respectively [3]. Group 3: Stock Specifics - Huahai Pharmaceutical had a daily increase of 7.63% with a turnover rate of 7.71% and a net capital flow of 266.08 million yuan [3]. - Guanhao Biological surged by 19.97% with a turnover rate of 28.68% and a net capital flow of 159.24 million yuan [3]. - Hainan Haiyao also performed well, increasing by 9.97% with a turnover rate of 6.18% and a net capital flow of 64.85 million yuan [3].

截至6月3日收盘，创新药概念上涨3.38%，位居概念板块涨幅第7，板块内，173股上涨，华纳药厂、舒 泰神、冠昊生物等20%涨停，万邦德、千红制药、昂利康等涨停，诺思兰德、科兴制药、海特生物等涨 幅居前，分别上涨18.82%、14.97%、13.18%。跌幅居前的有*ST苏吴、海创药业、百利天恒等，分别下 跌4.78%、3.73%、2.87%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 中韩自贸区 | 4.23 | 特钢概念 | -0.93 | | 细胞免疫治疗 | 3.87 | 医疗废物处理 | -0.51 | | 重组蛋白 | 3.64 | 果指数 | -0.41 | | 足球概念 | 3.56 | 无线充电 | -0.39 | | 毛发医疗 | 3.51 | 光热发电 | -0.33 | | CRO概念 | 3.41 | 深圳国企改革 | -0.24 | | 创新药 | 3.38 | F5G概念 | -0.23 | | 培育钻石 | 3.11 | 租售同权 | -0.22 | | 仿制药一致性评价 ...

6月3日，A股、港股市场集体上涨，创新药板块概念股持续走强。 相关ETF方面，截至收盘，创新药ETF天弘（517380）涨2.24%，年内累计涨幅达23.08%，位居全市场 行业类ETF涨幅第一，涨幅领先第二名超9%。成分股中，睿智医药涨超13%，亚盛医药-B涨超8%，华 海药业、联邦制药、和黄医药、贝达药业等股涨超7%。 创新药ETF天弘(517380)及联接基金(A类014564，C类014565)是全市场唯一一只跟踪恒生沪深港创新药 精选50指数的产品，该指数覆盖了沪、深、港三地创新药龙头，十大权重股包括百济神州、药明康德、 恒瑞医药、泰格医药等细分领域龙头，可谓是创新药"浓度"极高。同时，该ETF及联接基金（A类： 014564，C类：014565）采用量化指标优化，截至6月3日收盘，年内累计涨幅位居全市场行业类ETF涨 幅第一。 招银国际表示，我们认为，受益于创新药出海交易、国内集采政策优化、创新药丙类医保目录落地、医 疗设备招标复苏、内需复苏等积极因素推动，医药行业有望在 2025 年继续迎来估值修复。 消息面上，据第一财经，5月30日，在陆家嘴金融沙龙上，中国科学院院士马大为表示，我们有越来越 ...

Group 1 - The A-share market opened positively in June, with the Shanghai Composite Index closing at 3361.98 points, up 0.43% [1] - The A500 Index ETF (159351) experienced a slight decline of 0.31% during the day but saw a net subscription of 45 million units [1] - The A500 Index ETF recorded a total trading volume of 2.79 billion yuan, ranking second among similar products in the market and first in the Shenzhen market, with a turnover rate of 18.93% [1] Group 2 - In May, the National Press and Publication Administration approved 130 domestic and 14 imported online games, totaling 144 approvals, setting a new monthly record in nearly two years [1] - Major gaming industry stocks surged following the news, with Changyou Technology rising over 14%, Giant Network nearly 7%, and Perfect World over 5% [1] - Pharmaceutical stocks also maintained strong performance, with Huahai Pharmaceutical and Betta Pharmaceuticals both increasing over 7% [1] Group 3 - Short-term market dynamics are influenced by a mix of internal and external factors, but policy support, profit recovery, and the attractiveness of RMB assets provide a foundation for stability [1] - Investment strategies are recommended to focus on "core assets as a shield and technology growth as a spear," while paying attention to policy implementation and industry catalysts in June [1] Group 4 - The A500 Index ETF (159351) tracks the CSI A500 Index, consisting of 500 stocks with large market capitalization and good liquidity, providing a tool for investors to access representative A-share companies [2] - Investors can also consider the A500 Index ETF linked funds (Class A 022453; Class C 022454) to capitalize on the upward potential of quality core assets [2]

Group 1 - The A-share and Hong Kong stock markets saw a strong performance in the innovative drug sector, with the Tianhong Innovative Drug ETF (517380) closing up 2.24%, ranking first among innovative drug ETFs and twelfth in the overall ETF market, with a trading volume exceeding 11 million yuan [1] - The Tianhong Innovative Drug ETF was launched in 2021 and tracks the "Hang Seng Shanghai-Shenzhen Hong Kong Innovative Drug Selected 50" index, providing comprehensive coverage of the innovative drug industry across A-shares and Hong Kong stocks [1] - Key stocks in the ETF included Ruizhi Pharmaceutical, which rose over 13%, along with other notable gainers such as Tigermed, Hutchison China MediTech, Federal Pharmaceutical, and Huahai Pharmaceutical [1] Group 2 - Hansoh Pharmaceutical announced a licensing agreement with Regeneron Pharmaceuticals for the global exclusive rights to develop, produce, and commercialize HS-20094, excluding mainland China, Hong Kong, and Macau, with an upfront payment of $80 million and potential milestone payments of up to $1.93 billion [2] - The innovative drug sector is expected to continue being a primary focus for pharmaceutical investments, driven by increasing policy support and a shift from quantity and speed to quality and innovation in Chinese innovative drugs [4] - The number of original research drugs entering clinical stages in China has reached 704, surpassing the United States and positioning China as the global leader in this area [3]